Replimune Group Inc’s shares advanced to a 52-week high of $15.72 on Tuesday, closing at $15.69, as the biotechnology firm’s cancer treatment gained regulatory approval. The stock has rallied 174.3% over the past year, pushing its market capitalization to $1.47 billion.
The U.S. Food and Drug Administration granted approval for Replimune’s TUDRIQEV, a first-in-class oncolytic virus therapy used alongside a checkpoint inhibitor to treat advanced melanoma. The clearance has prompted upgrades from multiple analysts, with Wedbush raising its rating to Outperform from Neutral and lifting its price target to $19, citing strong launch potential. Leerink similarly upgraded Replimune to Outperform with a $17 target, while Cantor Fitzgerald maintained an Overweight stance.
Options data indicates an expected 5.6% move in the stock, reflecting heightened interest. InvestingPro analysis, however, flags potential overvaluation at current levels, noting high volatility as the shares trade near their annual peak.
